TY - JOUR
T1 - In vivo stability evaluation of Mg substituted low crystallinity ß-tricalcium phosphate granules fabricated through dissolution-precipitation reaction for bone regeneration
AU - Tripathi, Garima
AU - Sugiura, Yuki
AU - Tsuru, Kanji
AU - Ishikawa, Kunio
N1 - Funding Information:
This study was financially supported by AMED under Grant Number JP18im0502004 and a Grant-in-Aid for Young Researcher (Start-Aid) of Dr Garima Tripathi by the Japan Society for the Promotion of Science (JSPS) grant number: JP16H07061.
Publisher Copyright:
© 2018 IOP Publishing Ltd.
PY - 2018/8/15
Y1 - 2018/8/15
N2 - Although β-tricalcium phosphate (β-TCP) is widely used in clinical applications as a bone substitute owing to its positive tissue response and its ability to be replaced by new bone through a bone-remodeling process, it has the limitation of rapid resorption in vivo, which might become a reason for tissue atrophy and high crystallinity, which decrease biocompatibility. A reduction in the crystallinity might increase the biocompatibility of the bone substitute. To overcome the drawbacks of β-TCP, decrease in crystallinity and solubility, both are required. Therefore, in this study, the feasibility of fabricating Mg substituted low crystalline β-TCP (Mg-LC-β-TCP) granules formed in aqueous solution was evaluated in vivo focusing long-term adsorption and bone formation in bone defects formed in the rabbit femur using sintered β-TCP granules as a control. With Mg-LC-β-TCP, the resorption of the substitute was suppressed, and no tissue atrophy was observed even at 24 weeks post-implantation, whereas a few granules with surrounding tissue atrophy were observed at 12 weeks post-implantation. Tartrate-resistant acid phosphatase-staining indicated that the density of osteoclasts type cells with Mg-LC-β-TCP was significantly lower than that with β-TCP, and also the numbers of osteoblasts type cells with Mg-LC-β-TCP were significantly higher than that with β-TCP. It is suggested that Mg substitution to form low crystallinity β-TCP is a valuable way to overcome the limitations of β-TCP as a bone substitute.
AB - Although β-tricalcium phosphate (β-TCP) is widely used in clinical applications as a bone substitute owing to its positive tissue response and its ability to be replaced by new bone through a bone-remodeling process, it has the limitation of rapid resorption in vivo, which might become a reason for tissue atrophy and high crystallinity, which decrease biocompatibility. A reduction in the crystallinity might increase the biocompatibility of the bone substitute. To overcome the drawbacks of β-TCP, decrease in crystallinity and solubility, both are required. Therefore, in this study, the feasibility of fabricating Mg substituted low crystalline β-TCP (Mg-LC-β-TCP) granules formed in aqueous solution was evaluated in vivo focusing long-term adsorption and bone formation in bone defects formed in the rabbit femur using sintered β-TCP granules as a control. With Mg-LC-β-TCP, the resorption of the substitute was suppressed, and no tissue atrophy was observed even at 24 weeks post-implantation, whereas a few granules with surrounding tissue atrophy were observed at 12 weeks post-implantation. Tartrate-resistant acid phosphatase-staining indicated that the density of osteoclasts type cells with Mg-LC-β-TCP was significantly lower than that with β-TCP, and also the numbers of osteoblasts type cells with Mg-LC-β-TCP were significantly higher than that with β-TCP. It is suggested that Mg substitution to form low crystallinity β-TCP is a valuable way to overcome the limitations of β-TCP as a bone substitute.
UR - http://www.scopus.com/inward/record.url?scp=85055469538&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055469538&partnerID=8YFLogxK
U2 - 10.1088/1748-605X/aad385
DO - 10.1088/1748-605X/aad385
M3 - Article
C2 - 30010092
AN - SCOPUS:85055469538
VL - 13
JO - Biomedical Materials (Bristol)
JF - Biomedical Materials (Bristol)
SN - 1748-6041
IS - 6
M1 - 065002
ER -